| 规格 | 价格 | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| 药代性质 (ADME/PK) |
吸收、分布和排泄
实验表明，向兔子静脉注射纯碳悬浮液不会引起眼部炎症，尽管碳颗粒沉积在血管内。 |
|---|---|
| 毒性/毒理 (Toxicokinetics/TK) |
非人类毒性值
大鼠口服LD50 > 10,000 mg/kg 小鼠静脉注射LD50 440 mg/kg |
| 参考文献 | |
| 其他信息 |
根据世界卫生组织国际癌症研究机构 (IARC) 的说法，炭黑（空气中可吸入的游离颗粒）可能致癌。
活性炭是一种经过处理以提高吸附能力的黑色颗粒。如果在生产后未适当冷却，可能会自燃。 动物或植物来源的碳呈黑色粉末或颗粒状，与焦油或淀粉和水粘合剂混合，压制成规则的块状或煤球状。加热缓慢，在空气中易燃，尤其是在潮湿的情况下。 碳纳米管是由石墨烯圆柱体组成的富勒烯状纳米结构。其末端由五边形环封闭。 碳是一种非金属四价元素，符号为C，原子序数为6，原子量为12。 碳是一种矿物。 另见：炭黑（有子类）；石墨（有子类）。活性炭（有子类）……查看更多…… |
| 分子式 |
C
|
|---|---|
| 精确质量 |
12
|
| CAS号 |
7440-44-0
|
| 相关CAS号 |
Carbon-13C;14762-74-4
|
| PubChem CID |
5462310
|
| 外观&性状 |
Steel gray to black greasy feeling solid.
|
| 密度 |
~1.7 g/mL at 25 °C(lit.)
|
| 沸点 |
500-600 °C(lit.)
|
| 熔点 |
Melting point equals greater than 3500 °C
; MW: 760.642 Yellow needles of plates. MP: >280 °C. Soluble in organic solvents /Fullerene-60/
; MW: 840.749. Red-brown solid. MP: >280 °C. Soluble in benzene, toluene /Fullerene-70/
; >3500 °C
; 4489 °C
; 6602 °F (Sublimes)
|
| 闪点 |
>230 °F
|
| 蒸汽压 |
<0.1 mm Hg ( 20 °C)
|
| LogP |
0.6
|
| tPSA |
0
|
| 氢键供体(HBD)数目 |
0
|
| 氢键受体(HBA)数目 |
0
|
| 可旋转键数目(RBC) |
0
|
| 重原子数目 |
1
|
| 分子复杂度/Complexity |
0
|
| 定义原子立体中心数目 |
0
|
| SMILES |
[C]
|
| InChi Key |
OKTJSMMVPCPJKN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C
|
| 化学名 |
carbon
|
| HS Tariff Code |
2934.99.9001
|
| 存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| 运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| 溶解度 (体外实验) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| 溶解度 (体内实验) |
注意: 如下所列的是一些常用的体内动物实验溶解配方，主要用于溶解难溶或不溶于水的产品（水溶度<1 mg/mL）。 建议您先取少量样品进行尝试，如该配方可行，再根据实验需求增加样品量。
注射用配方
注射用配方1: DMSO : Tween 80： Saline = 10 : 5 : 85 (如： 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)(IP/IV/IM/SC等) *生理盐水/Saline的制备：将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中，得到澄清溶液。 注射用配方 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline) 注射用配方 3: DMSO : Corn oil = 10 : 90 (如： 100 μL DMSO → 900 μL Corn oil) 示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液，加到 900 μL Corn oil/玉米油中, 混合均匀。 View More
注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如：100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)] 口服配方
口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠) 口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素) 示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中，得到0.5%CMC-Na澄清溶液；然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中，得到悬浮液。 View More
口服配方 3: 溶解于 PEG400 (聚乙二醇400) 请根据您的实验动物和给药方式选择适当的溶解配方/方案： 1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL； 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果，工作液请现配现用！ 6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
计算结果:
工作液浓度： mg/mL；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH2O，混匀澄清。
(1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
(2) 一定要按顺序加入溶剂 (助溶剂) 。
Link: https://clinicaltrials.gov/ct2/show/NCT06608277
Conditions:Posttraumatic Headache|Posttraumatic Stress DisorderLink: https://clinicaltrials.gov/ct2/show/NCT01709292
Conditions:Thyroid CancerLink: https://clinicaltrials.gov/ct2/show/NCT06141473
Conditions:Multiple Sclerosis
Title:Measuring Acute Drug Demand in Humans
Status:Suspended
updateDate:2026-02-18
Ctid:NCT05829655
Link: https://clinicaltrials.gov/ct2/show/NCT05829655
Conditions:Opioid Use Disorder|Opioid DependenceLink: https://clinicaltrials.gov/ct2/show/NCT05471479
Conditions:Charcoal, Decontamination, PoisoningLink: https://clinicaltrials.gov/ct2/show/NCT07299877
Conditions:Brachial Plexus BlocksLink: https://clinicaltrials.gov/ct2/show/NCT07220031
Conditions:Osmolality Disturbance|Lab InterferenceLink: https://clinicaltrials.gov/ct2/show/NCT02969746
Conditions:Anticoagulants; Circulating, Hemorrhagic DisorderLink: https://clinicaltrials.gov/ct2/show/NCT06790290
Conditions:Pneumococcal Disease, InvasiveLink: https://clinicaltrials.gov/ct2/show/NCT06906874
Conditions:End Stage Renal Disease (ESRD)|CKD 5D, Hemodialysis|CKD-MBD - Chronic Kidney Disease Mineral and Bone DisorderLink: https://clinicaltrials.gov/ct2/show/NCT07108881
Conditions:Cesarean Section Complications|Spinal Anesthesia|Hypotension|Hypovolemia|Sympathetic Blockade|Fluid LoadingLink: https://clinicaltrials.gov/ct2/show/NCT07096765
Conditions:Nerve BlockLink: https://clinicaltrials.gov/ct2/show/NCT06806007
Conditions:Pulmonary Dysfunction|Spastic DiaplegiaLink: https://clinicaltrials.gov/ct2/show/NCT02813460
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT06422403
Conditions:Carcinoma, Hepatocellular|Gastric Adenocarcinoma|GastroEsophageal Cancer|Oesophageal Cancer|Non-small Cell Lung Cancer|Head and Neck Squamous Cell CarcinomaLink: https://clinicaltrials.gov/ct2/show/NCT06579066
Conditions:Chronic Kidney Disease|Uremic PruritusLink: https://clinicaltrials.gov/ct2/show/NCT06491485
Conditions:Postoperative PainLink: https://clinicaltrials.gov/ct2/show/NCT06219967
Conditions:OverdoseLink: https://clinicaltrials.gov/ct2/show/NCT06209372
Conditions:Efficiency|Spinal Anesthesia|BlockLink: https://clinicaltrials.gov/ct2/show/NCT06355960
Conditions:Drug Use|DexmedetomidineLink: https://clinicaltrials.gov/ct2/show/NCT05752734
Conditions:Anesthesia|Analgesia|Acute PainLink: https://clinicaltrials.gov/ct2/show/NCT04713631
Conditions:Crohn's DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT04631107
Conditions:Obstructive Sleep ApneaLink: https://clinicaltrials.gov/ct2/show/NCT04767776
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT05540431
Conditions:Uremic ToxinLink: https://clinicaltrials.gov/ct2/show/NCT03762343
Conditions:Posterior Fossa TumorLink: https://clinicaltrials.gov/ct2/show/NCT03802487
Conditions:Type 2 Diabetes Mellitus|Healthy SubjectsLink: https://clinicaltrials.gov/ct2/show/NCT04928950
Conditions:Lung CancerLink: https://clinicaltrials.gov/ct2/show/NCT04540848
Conditions:Post Operative PainLink: https://clinicaltrials.gov/ct2/show/NCT03572062
Conditions:Respiratory Tract InfectionLink: https://clinicaltrials.gov/ct2/show/NCT04739917
Conditions:Malaria, VivaxLink: https://clinicaltrials.gov/ct2/show/NCT03311373
Conditions:Chronic Obstructive Pulmonary DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT04311645
Conditions:Chronic Kidney Disease stage3Link: https://clinicaltrials.gov/ct2/show/NCT01336647
Conditions:PediculosisLink: https://clinicaltrials.gov/ct2/show/NCT03668964
Conditions:Healthy VolunteersLink: https://clinicaltrials.gov/ct2/show/NCT04135534
Conditions:Post Operative Pain|Opioid Side EffectsLink: https://clinicaltrials.gov/ct2/show/NCT03718390
Conditions:Gastric Retention|HealthyLink: https://clinicaltrials.gov/ct2/show/NCT01389752
Conditions:Depressive Disorder, MajorLink: https://clinicaltrials.gov/ct2/show/NCT01139164
Conditions:Hematological MalignanciesLink: https://clinicaltrials.gov/ct2/show/NCT02426632
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT02083068
Conditions:MalariaLink: https://clinicaltrials.gov/ct2/show/NCT01231568
Conditions:CancerLink: https://clinicaltrials.gov/ct2/show/NCT00495274
Conditions:Sleep Initiation and Maintenance DisordersLink: https://clinicaltrials.gov/ct2/show/NCT00548769
Conditions:Multiple SclerosisLink: https://clinicaltrials.gov/ct2/show/NCT03202459
Conditions:Postoperative Complications|Postoperative Nausea and VomitingLink: https://clinicaltrials.gov/ct2/show/NCT01424462
Conditions:Multiple Sclerosis, Relapsing-RemittingLink: https://clinicaltrials.gov/ct2/show/NCT02737371
Conditions:Invasive AspergillosisLink: https://clinicaltrials.gov/ct2/show/NCT02691325
Conditions:Pulmonary Disease, Chronic ObstructiveLink: https://clinicaltrials.gov/ct2/show/NCT03033667
Conditions:Metabolism DisorderLink: https://clinicaltrials.gov/ct2/show/NCT01257191
Conditions:Hypersensitivity, Immediate|Atopic HypersensitivityLink: https://clinicaltrials.gov/ct2/show/NCT01409369
Conditions:Healthy VolunteerLink: https://clinicaltrials.gov/ct2/show/NCT01796717
Conditions:Nosocomial PneumoniaLink: https://clinicaltrials.gov/ct2/show/NCT02003313
Conditions:MeningitisLink: https://clinicaltrials.gov/ct2/show/NCT01226771
Conditions:Hepatitis CLink: https://clinicaltrials.gov/ct2/show/NCT01863888
Conditions:Multiple SclerosisLink: https://clinicaltrials.gov/ct2/show/NCT01679028
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT00823264
Conditions:Phenytoin ToxicityLink: https://clinicaltrials.gov/ct2/show/NCT01489995
Conditions:Fabry DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT01838967
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT01580033
Conditions:Meningitis|InfluenzaLink: https://clinicaltrials.gov/ct2/show/NCT01199627
Conditions:Hip Replacement, TotalLink: https://clinicaltrials.gov/ct2/show/NCT01737437
Conditions:Neurosurgical PatientsLink: https://clinicaltrials.gov/ct2/show/NCT00211562
Conditions:SchizophreniaLink: https://clinicaltrials.gov/ct2/show/NCT01428908
Conditions:Group A, C Polysaccharide Meningitis|Type b Haemophilus InfluenzaLink: https://clinicaltrials.gov/ct2/show/NCT00419146
Conditions:Schizophrenia|Schizophreniform Disorders|Schizoaffective Disorder|Psychotic DisordersLink: https://clinicaltrials.gov/ct2/show/NCT00592137
Conditions:Obesity|Energy MetabolismInvivoChem的所有产品仅用于作科学研究，不面向患者销售
Copyright 2020 InvivoChem LLC | All Rights Reserved 粤ICP备20063088号-1
粤公网安备 44011102003439号
463611831
